癌症治療藥品開發動向：腎臟癌

癌症治療藥品開發動向：腎臟癌 是由出版商Espicom Business Intelligence在2007年05月所出版的。 這份英文市場調查報告書包含104 PAGES 價格從美金1390起跳。

簡介

目錄

The renal cell carcinoma (RCC) market was estimated to be worth around US$1 billion in 2006, with a growth rate of 36% YoY. It has constituted a relatively small segment of the oncology market but has more recently attracted considerable research and development investment from big pharmaceutical, biotechnology and specialty pharma companies.

The market is currently driven by the use of the following immunomodulating agents: Schering-Plough' s Intron A (interferon [IFN] alpha-2b), Roche' s Roferon-A (IFN alpha-2a) and Novartis' Proleukin (aldesleukin); with new market entrants Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) and Pfizer' s Sutent (sunitinib) making significant inroads into the market in 2006, their first year of sales.

The launch of more effective targeted agents and greater use of combination therapies instead of monotherapies, with the establishment of existing and new agents as adjuvant therapy in early-stage disease will contribute to the RCC market' s most eventful decade.

There are significant opportunities for effective new products to expand rapidly, as a large percentage of patients are currently not treated with drug therapies and are not cured by surgery alone. These patients are candidates for adjuvant therapy.

We forecast that sales of RCC treatments will increase to US$3 billion by 2009 and over US$6 billion by 2012 due to the launch of up to nine new therapies. The RCC market is in its most exciting phase of evolution!

• What are the reasons behind the expected increase in the patient population with RCC?
• What impact will the new oral agents have on a market currently dominated by injectables?
• Why is only 25% of the global RCC market in Europe?
• What are the prospects for GSK' s pazopanib and what revenue contribution might it make in 2012?
• What challenges must Novartis overcome with Proleukin and its new product everolimus if it is to maintain market presence?
• What factors are limiting Wilex' Rencarex commercialisation?

• RENAL CELL CARCINOMA
  • EXECUTIVE SUMMARY
• THE FACTS
  • What is RCC and why are we interested in it?
    • Figure 6.1: Structure of the Kidney
    • PATIENT STATISTICS
      • Incidence, diagnosis rates and treatment; now and in the future
        • Figure 6.2: World age-standardised incidence rates for kidney cancer, selected countries, 2002 estimates
    • PATIENT MODEL
      • The number of patients with RCC will have a CAGR 2005A-2012E of 2.67%.
        • Table 6.1: Summary of Patient Population Forecasts
    • DRUG GROWTH DRIVERS
    • DRUG GROWTH RISKS/DAMPENERS
• THE MARKET
  • GLOBAL CANCER MARKET
    • Figure 6.3: Global Cancer Drug Sales (including Supportive Care) in 2006 (US$47 billion)
    • Figure 6.4: Global Cancer Sales 2004A-2012E
  • THE RCC MARKET
  • GLOBAL SALES SPLIT
    • Figure 6.5: Global sales split (2006)
  • US market
    • Figure 6.6: RCC US Drugs Sales Split (2006A)
  • European market
    • Figure 6.7: RCC European Drugs Sales Split (2006A)
  • Japanese market
  • The major players
  • Players and Products in 2006
  • Players and products in 2012
    • Figure 6.9: Global Market share of RCC players by sales (Dec 2012E)
  • CURRENT TREATMENTS
    • Leading Brands
      • Table 6.2: Comparison of Leading RCC Agents
    • Current Products' Patent Exposure
      • Table 6.3: Patent Exposure of Leading Brands
  • ANALYSIS OF LEADING BRANDS
    • Immunomodulating agents
      • Immunomodulating agents
        • Interferon (IFN) alpha
        • Intron A/PEG-Intron (Schering-Plough)
        • Roferon-A/Pegasys (Roche)
          • Novelty/rationale for mechanism of action
          • Proof of concept/clinical data
          • Management/clinical expertise
          • Competition within the marketplace/gaining share of voice
          • Risks associated with developing a drug within a therapeutic class
          • Filings and approval
          • Sales forecasts and assumptions
          • Table 6.4: Sales forecasts for interferon products
          • Competitor Ratio Analysis
    • Proleukin (Novartis/Chiron)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Nexavar (Bayer/Onyx Pharmaceuticals)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Sutent (Pfizer)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005A- 2012E
  • Table 6.5: Sales Forecasts of Current Leading RCC Drugs (US$ millions)
  • Model assumptions
  • NEW DRUGS IN R&D
    • Table 6.6: Drugs in Development to Treat RCC
• ANALYSIS OF PHASE III DRUGS
  • Table 6.7: New Drugs in Phase III Development to Treat RCC
    • Avastin (Roche/Genentech/Chugai)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Everolimus (Novartis)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Pazopanib (GlaxoSmithKline)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Rencarex (Wilex)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Torisel (Wyeth)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • TroVax (Oxford BioMedica/sanofi-aventis)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Tykerb (GlaxoSmithKline)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
• GLOBAL SALES FORECASTS OF PHASE III RCC DRUGS 2006E- 2012E
  • Table 6.8: Sales Forecasts of Phase III Developmental RCC Drugs (US$ million)
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • Table 6.9: New Drugs in Early Clinical Development to Treat RCC
  • Immunomodulators
  • Angiogenic inhibitors
  • Novel agents
  • Immunomodulators
    • rIL-21 (ZymoGenetics/Novo Nordisk)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Revlimid (Celgene)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Talactoferrin (Agennix)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
  • Angiogenesis inhibitors
    • ABT-510 (Abbott)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
  • Novel agents
    • AS1411 (Antisoma)
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace/gaining share of voice
      • Risks associated with developing a drug within a therapeutic class
      • Filings and approval
      • Sales forecasts and assumptions
      • Competitor Ratio Analysis
    • Other Interesting Phase II Drugs
      • ABT-751 (Abbott)
      • Recentin (AstraZeneca)
      • GTI-2040 (Lorus Therapeutics)
      • Ipilimumab (Medarex/Bristol-Myers Squibb)
      • Ixabepilone (Bristol-Myers Squibb)
      • Vatalinib (Novartis/Bayer Schering Pharma)
      • Volociximab (PDL BioPharma/Biogen Idec)
      • XL880 (Exelixis)
• GLOBAL SALES FORECASTS OF PHASE II RCC DRUGS 2006A - 2012E
  • Table 6.10: Sales Forecasts of Phase II Developmental RCC Drugs (US$ million)
    • Model assumptions
• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • Table 6.11: Rating Score for Clinical Rating
  • Figure 6.11: CR Analysis of RCC Agents Approved by 2012 - Based on Drug Class
  • COMPETITOR RATIO ANALYSIS - COMPANIES
    • Figure 6.12: CR Analysis of RCC Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Table 6.12: Summary of Key Companies and Drugs in the RCC Market by 2012
    • Winners (alphabetical)
    • Losers
• DISCONTINUATION OF DRUGS
  • Table 6.13: Drugs Discontinued (or ' on hold' ) from Clinical Development in RCC
• APPENDIX 1
  • Figure 6.13: RCC Tumour Staging Systems
  • Tumor, Node, Metastasis (TNM) Staging of Renal Cell Carcinoma
• APPENDIX 2
  • Phase Transition Probability
    • Table 6.14: Probability of Launch
• Appendix 3
  • Patient Model
    • Table 6.15: Summary of US RCC Patient Population Forecasts
    • Table 6.16: Summary of Europe (Top 5) RCC Patient Population Forecasts
    • Table 6.17: Summary of Japan RCC Patient Population Forecasts
• Appendix 4
  • Table 18: Global RCC Drugs Sales 2005A-2012E
• APPENDIX 5
  • Competitor Ratio Analysis Criteria
  • Table 6.19: Key RCC Drugs on the Market by 2012
• GLOSSARY
• REFERENCES
• ACRONYMS

相關商品

矚目市場調查報告書

癌症治療藥品開發動向

Cancer Drug Discoveries: what the future holds

價格 : US $ 5690

出版日期 : 2007年05月

藥物開發相關市場調查報告書

乳癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

白血病，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

Espicom Business Intelligence發行的製藥相關市場調查報告書

疼痛治療藥市場的發展：侵害受容性及神經性疼痛治療藥的開發

Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development

價格 : US $ 2265

出版日期 : 2012年01月

世界非專利藥品市場

World Generic Markets

價格 : US $ 1080

出版日期 : 2012年01月

全球醫藥品市場展望

The Outlook for Pharmaceuticals Worldwide

價格 : US $ 17490

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!